Cosmo Pharmaceuticals N.V. Stock Forecast for 2023 - 2025 - 2030
Updated on 03/18/2024
Cosmo Pharmaceuticals N.V. Stock Forecast and Price Target
If the average price target of CHF84.93 set by distinguished experts for Cosmo Pharmaceuticals N.V. over the past few weeks is reached this year, there would be a potential upside of approximately 25.82% from the last closing price in March, 2024. This potential increase is based on a high estimate of CHF89.96 and a low estimate of CHF70.67. If you're looking for Cosmo Pharmaceuticals N.V. (COPN) stock information, you might also want to check out DURECT (NasdaqCM:DRRX).
25.82% Upside
Cosmo Pharmaceuticals N.V. Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Cosmo Pharmaceuticals N.V.'s Price has grown, increasing from CHF0.00 to CHF0.00 – an increase of 100.00%. For next year, the 4 analysts predict Fair Value of CHF45.50, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof CHF238.84, which would mean a seven-year growth forecast of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ARGX Stock Forecast | argenx | Outperform |
4
|
359.20€ | Buy/Sell | 531.81€ | 22.22% |
GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr2.15k | Buy/Sell | kr2.71k | 17.43% |
REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
52.74€ | Buy/Sell | 48.61€ | -5.76% |
ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr686.00 | Buy/Sell | kr357.00 | 15.16% |
ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
35.99€ | Buy/Sell | 42.52€ | 16.70% |
Cosmo Pharmaceuticals N.V. Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Cosmo Pharmaceuticals N.V.'s Revenue has grown, increasing from CHF60.95M to CHF102.09M – an increase of 67.50%. For next year, the 4 analysts predict Revenue of CHF141.33M, which would mean an increase of 38.44%. Over the next seven years, the pros' prediction is Revenueof CHF394.00M, which would mean a seven-year growth forecast of 285.93%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£19.10 | Buy/Sell | £28.11 | 55.34% |
ALKS Stock Forecast | Alkermes | Outperform |
10
|
$28.60 | Buy/Sell | $33.27 | 18.88% |
ALK B Stock Forecast | ALK-Abelló A/S | Outperform |
13
|
kr129.70 | Buy/Sell | kr109.25 | 2.54% |
Cosmo Pharmaceuticals N.V. Dividend per Share Forecast for 2023 - 2025 - 2030
Cosmo Pharmaceuticals N.V.'s Dividend per Share has increased by 10.53% In the last year, going from CHF0.95 to CHF1.05. According to 3 prominent analysts, Cosmo Pharmaceuticals N.V.'s Dividend per Share will fall by 19.05% in the next year, reaching CHF0.85. For the next seven years, the forecast is for Dividend per Share to grow by 116.19%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MOR Stock Forecast | MorphoSys | Outperform |
6
|
65.52€ | Buy/Sell | 28.78€ | 3.79% |
EVT Stock Forecast | Evotec | Outperform |
14
|
13.10€ | Buy/Sell | 37.33€ | 90.84% |
INDV Stock Forecast | Indivior PLC | Buy |
14
|
£16.50 | Buy/Sell | £28.89 | 92.00% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ALM Stock Forecast | Almirall | Outperform |
16
|
8.23€ | Buy/Sell | 11.39€ | 39.73% |
SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$32.43 | Buy/Sell | $41.00 | 24.88% |
FAE Stock Forecast | Faes Farma | Hold |
18
|
3.00€ | Buy/Sell | 3.90€ | 21.67% |
Cosmo Pharmaceuticals N.V. EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Cosmo Pharmaceuticals N.V.'s EBITDA has grown by 579.37%, from CHF6.06M to CHF41.17M. For the next year, analysts are expecting EBITDA to reach CHF67.11M – an increase of 63.01%. Over the next seven years, experts predict that EBITDA will grow by 519.38%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
PHM Stock Forecast | Pharma Mar | Outperform |
13
|
30.62€ | Buy/Sell | 50.20€ | 56.76% |
BSLN Stock Forecast | Basilea Pharmaceutica | Outperform |
6
|
CHF38.25 | Buy/Sell | CHF65.63 | 72.55% |
DBV Stock Forecast | DBV Technologies | Outperform |
5
|
1.43€ | Buy/Sell | 4.07€ | 138.46% |
Cosmo Pharmaceuticals N.V. EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Cosmo Pharmaceuticals N.V.'s EBIT has grown from CHF1.81M to CHF28.06M – a 1450.28% increase. Next year, analysts are expecting EBIT to reach CHF53.83M – an increase of 91.84%. Over the next seven years, the forecast is for EBIT to grow by 762.44%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MOLN Stock Forecast | Molecular Partners | Outperform |
4
|
CHF3.69 | Buy/Sell | CHF9.50 | 157.45% |
ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$0.93 | Buy/Sell | $3.50 | 276.34% |
DRRX Stock Forecast | DURECT | Outperform |
9
|
$1.01 | Buy/Sell | $6.75 | 568.32% |
Cosmo Pharmaceuticals N.V. EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Cosmo Pharmaceuticals N.V.'s EPS has grown, increasing from CHF-0.55 to CHF0.00 – an increase of 100.00%. For next year, the 4 analysts predict EPS of CHF2.29, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof CHF12.02, which would mean a seven-year growth forecast of 100.00%.